Zoledronate

Overview

Zoledronate (zoledronic acid) is a bisphosphonate used in dogs and cats primarily for the management of malignancy-associated bone disease and hypercalcemia. It is administered intravenously and is most commonly used as an adjunctive treatment for osteolytic bone pain associated with skeletal malignancies.

Mechanism of Action (MOA): Bisphosphonates inhibit bone resorption by binding to hydroxyapatite crystals and suppressing osteoclast activity without inhibiting bone mineralization at therapeutic concentrations. Zoledronate primarily targets the osteoclast enzyme farnesyl pyrophosphate synthase, leading to impaired osteoclast function and induction of osteoclast apoptosis. Urinary calcium and phosphorus excretion may increase, and hypocalcemia, hypophosphatemia, and hypermagnesemia can occur.

Zoledronate has roughly 100× the antiresorptive potency of pamidronate, which is why it uses a much shorter infusion time (15 min vs 2–4 h for pamidronate) and lower mg/kg doses.

NIOSH classifies zoledronic acid as a group-3 hazardous drug (non-antineoplastic with adverse reproductive effects). Use appropriate PPE during handling, and advise owners to wear PPE when handling animal waste (urine, faeces, vomit) after treatment.

In dogs, zoledronate has been used for osteolytic bone pain associated with primary and metastatic skeletal malignancies, particularly osteosarcoma, and for hypercalcemia associated with malignancy. In cats, the drug has been reported to slow tumor growth and reduce pathologic bone turnover in oral squamous cell carcinoma involving bone invasion.

Zoledronate is administered as an intravenous infusion over no less than 15 minutes and appears generally well tolerated in veterinary patients, including some with comorbidities. However, electrolyte abnormalities and renal toxicity may occur, making renal function assessment and adequate hydration important before administration.

Brand-confusion warning: do not confuse ZOMeta (zoledronate — this drug) with ZIMeta (dipyrone); the two brand names look almost identical on packaging.

Indications

Zoledronate is primarily used in dogs and cats as an adjunctive treatment for malignancy-associated bone disease, osteolytic pain, and hypercalcemia related to neoplastic disorders.

• Hypercalcemia of malignancy: Used in dogs for adjunctive treatment of hypercalcemia associated with neoplastic disease.
• Osteolytic bone pain: Used as an adjunctive analgesic treatment for osteolytic bone pain associated with skeletal malignancies, especially osteosarcoma in dogs.
• Primary and metastatic skeletal malignancies: May help reduce pathologic bone turnover associated with malignant bone disease in dogs.
• Bone-invasive oral squamous cell carcinoma: Used in cats with oral squamous cell carcinoma involving bone invasion to help slow tumor growth and reduce tumor-associated bone destruction.
• Anal sac apocrine adenocarcinoma hypercalcaemia : May be considered in anal sac apocrine gland adenocarcinoma with severe hypercalcaemia, particularly preoperatively — alongside saline diuresis and/or low-dose prednisone.
• Chondrosarcoma bone pain: May alleviate bone pain in chondrosarcoma— included with NSAIDs, tramadol, and gabapentin as multimodal analgesia for primary chondrosarcoma of the rib or appendicular skeleton.
• Chondroprotection in experimental OA : Chondroprotective effect demonstrated in dogs with experimentally induced osteoarthritis— experimental finding, not yet a routine clinical indication, but useful context for evolving OA-modifying research.
• Direct antitumor activity : In vitro cytotoxic / cytostatic effects on human and canine osteosarcoma cell lines have been documented, along with bone-preserving activity at the primary tumor in a mouse model of canine OSA, antiangiogenic effects, and inhibition of cell migration in certain cancers. Explains why zoledronate is more than just bone-pain palliation in oncology protocols.

Dosage (Reference)

Dog

In dogs, zoledronate is administered as a slow intravenous infusion for management of malignancy-associated hypercalcemia and osteosarcoma-associated bone pain. Infusion administration should always occur over at least 15 minutes.

Cat

In cats, zoledronate has been used as an adjunctive treatment for bone-invasive oral squamous cell carcinoma and is administered as a slow intravenous infusion.

Warnings & Precautions

Zoledronate is a potent bisphosphonate that may cause renal toxicity and electrolyte abnormalities. Careful patient selection, hydration, and renal monitoring are important before and after administration in dogs and cats.

• Renal impairment: Contraindicated in patients with severe renal impairment due to the risk of renal injury and drug accumulation.
• Nephrotoxicity: Zoledronate may cause renal toxicity and should be used cautiously in patients receiving nephrotoxic medications or those with moderate renal dysfunction.
• Electrolyte abnormalities: Hypocalcemia, hypophosphatemia, and hypermagnesemia may occur following administration; monitor patients with pre-existing electrolyte or mineral metabolism disorders carefully.
• Hypocalcemia: Contraindicated in patients with pre-existing hypocalcemia until corrected.
• Patient hydration: Adequate hydration is recommended prior to treatment to help reduce the risk of renal complications.
• Infusion administration: Administer only as a slow IV infusion over no less than 15 minutes; rapid administration may increase the risk of renal toxicity.
• Extravasation risk: Tissue irritation may occur if extravasation develops during infusion administration.
• Osteonecrosis of the jaw: Osteonecrosis of the jaw has been reported following treatment.
• Pregnancy and reproduction: Safety has not been established in pregnant animals and the drug should only be used when maternal benefits outweigh potential fetal risks.
• Hypersensitivity: Contraindicated in patients with known hypersensitivity to zoledronic acid.
• NIOSH hazardous-drug handling: Use appropriate PPE during preparation and administration ( NIOSH hazardous-drug status); advise owners to use PPE when handling animal waste (urine, faeces, vomit) post-treatment.
• Lactation — extreme caution: Lactation — milk excretion of zoledronic acid is unknown; neonatal exposure could have effects persisting for weeks to months. Use with extreme caution in lactating animals; consider milk replacer.
• Pre-each-dose CBC + biochem: CBC + biochemistry profile checked BEFORE every zoledronate infusion (not just at baseline). Patients should be closely monitored after administration; no long-term follow-up studies of repeat zoledronate dosing exist in dogs.
• Renal-impairment PK pearl — AUC ↑: PK in renal impairment — total drug exposure (area under the curve) INCREASES with worsening renal impairment. Mild-to-moderate azotemia means more drug exposure per dose. dosage adjustments are not necessary for mild-to-moderate renal impairment but caution still applies.

Drug Interactions

Clinically important interactions with zoledronate are primarily related to additive effects on renal function and calcium balance. Additional monitoring is recommended when zoledronate is administered with the following medications.

• Aminoglycosides: May enhance the hypocalcemic effects of zoledronate; monitor calcium concentrations closely.
• Corticosteroids (e.g., dexamethasone, prednisolone, fludrocortisone): Concurrent use may further affect calcium balance and requires monitoring.
• Loop diuretics (e.g., furosemide): May increase calcium excretion and enhance hypocalcemic effects.
• Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cisplatin): Concurrent use may increase the risk of renal toxicity.
• NSAIDs (e.g., carprofen, meloxicam): Use cautiously due to the potential for additive nephrotoxic effects.
• Thiazide diuretics (e.g., hydrochlorothiazide): May promote calcium retention and reduce the hypocalcemic effects of zoledronate.
• NEVER Ca/Mg-containing IV fluids (LRS, Plasmalyte, Ringer’s): Compatibility rule — NEVER mix zoledronate with IV fluids containing divalent cations (LRS, Plasmalyte, Ringer’s). Use 0.9% sodium chloride or 5% dextrose ONLY in a DEDICATED IV line. Refrigerated solutions equilibrate to room temperature before administration.
• Incompatible with dantrolene, diazepam, phenytoin: Pharmaceutical incompatibilities — zoledronate is reportedly INCOMPATIBLE with dantrolene, diazepam, and phenytoin sodium. Do not co-administer or share a line with these drugs.
• Y-site compatibility — many common drugs OK (Plumb’s): Y-site compatibility — zoledronate is reportedly Y-site compatible with many common drugs including carboplatin, cisplatin, cyclophosphamide, doxorubicin, vincristine, dexamethasone sodium phosphate, dexmedetomidine, fentanyl, hydromorphone, morphine, ondansetron, midazolam, mannitol, potassium chloride. Always reverify specific combinations with a hospital pharmacist.

Side Effects & Overdose

Side Effects

Zoledronate administered as a 15-minute intravenous infusion appears generally well tolerated in veterinary patients. Most adverse effects are related to renal function abnormalities or electrolyte disturbances.

• Azotemia: Reported in dogs following administration, although concurrent medications may have contributed in some cases.
• Acute kidney injury: Acute renal injury has been reported in dogs and appears to be uncommon and usually mild to moderate in severity.
• Electrolyte abnormalities: Hypocalcemia has been reported following treatment.
• Gastrointestinal effects: Vomiting and diarrhea have been reported in dogs receiving zoledronate.
• Osteonecrosis of the jaw: Osteonecrosis involving the jaw has been reported following treatment.
• Extravasation irritation: Tissue irritation may occur if the drug extravasates during intravenous administration.
• Quantitative AKI rate 13.6%: Quantitative AKI data — 13.6% of dogs developed AKI after at least one ZOL dose (15.9% by IRIS criteria); mostly grade I-II; mean time to AKI was 35 days post-first-dose; treatment discontinued in 2.3% for azotemia progression.
• 79% AE-free rate : Tolerability data — 79% (90/114) of zoledronate infusions had NO adverse events. Most common AEs were diarrhoea, AKI, lethargy, and oral bleeding (mostly grade 1-2). Symptomatic hypocalcaemia was rare.

Overdose

Overdose of zoledronate may result in clinically significant electrolyte disturbances and renal toxicity. Careful monitoring and correction of abnormalities are required.

• Hypocalcemia: Severe hypocalcemia may occur and can lead to tetany.
• Electrolyte disturbances: Hypophosphatemia and hypomagnesemia may develop following overdose.
• Cardiac complications: Severe hypocalcemia has been associated with atrial fibrillation.
• Renal toxicity: Risk of renal injury increases with rapid infusion administration and excessive dosing.
• Management: Clinically significant electrolyte abnormalities should be identified and corrected promptly with supportive care and monitoring.
• 24-h poison consultation: Call a 24-h veterinary poison-consultation centre for suspected zoledronate overdose — individualised supportive-care advice.

Key Notes

Practical clinical considerations that may help optimize the safe and effective use of zoledronate in dogs and cats:

• Potency advantage: Zoledronate is a highly potent bisphosphonate and can be administered with shorter infusion times compared with some other bisphosphonates.
• Adjunctive role: Most commonly incorporated into multimodal oncology and palliative care protocols rather than used as a sole therapy.
• Bone turnover suppression: Helps reduce pathologic bone resorption associated with malignant skeletal disease.
• Radiation therapy protocols: May be incorporated into treatment protocols alongside ionizing radiation in dogs with osteosarcoma-associated bone pain.
• Monitoring trends: Serial monitoring of renal values and electrolytes may help guide repeated treatment protocols.
• Repeated administration: Long-term treatment protocols often involve scheduled repeat infusions at multiweek intervals.
• Oncology-focused use: Primarily reserved for patients with malignant bone disease or malignancy-associated hypercalcemia rather than routine orthopedic pain management.
• Dog PK pearls (Vd 0.3 L/kg, t½ 2.2 h): In 4 healthy dogs given 15-min IV— volume of distribution 0.3 L/kg, half-life 2.2 hours. In humans 50-75% of dose is incorporated into bone with terminal t½ 146 hours; the shorter animal t½ likely reflects sampling window rather than rapid clearance.
• Farnesyl pyrophosphate synthase target: Molecular target — zoledronate’s primary target is the osteoclast enzyme farnesyl pyrophosphate synthase. Inhibition disrupts the mevalonate pathway, depleting downstream isoprenoids needed for osteoclast survival.
• Calcium-response timing: reduction in calcium level seen in 1-3 days; ionised calcium decreased by a median of 31% (range 7-70%) after a median of 4 days. Plan re-check ionised calcium at 3-5 days post-infusion.
• Storage + diluted shelf life: Storage and diluted shelf life — store zoledronate at room temperature 25°C; excursions to 15-30°C permitted. Diluted concentrate (0.8 mg/mL) stored refrigerated 2-8°C; total time between dilution and completion of administration must NOT exceed 24 hours.
•  Monitoring panel: (1) baseline and periodic serum renal chemistry + electrolytes: calcium (total + ionised), phosphorus, potassium, magnesium, plus hydration status, before EACH dose; (2) baseline and periodic CBC; (3) baseline and periodic bone-turnover markers (bone-specific ALP, urine N-telopeptide); (4) baseline and periodic urinalysis.